Erythropoietin (EPO) Market Report: 2012 Edition
With the advent of novel technology, companies operating in the healthcare/science/pharmaceutical/therapeutic area are now scaling new heights. Also this industry is boosted by the rising number of incidences of health related issues emanating from the changing lifestyle and rapidly evolving surrounding environment.
Amongst the respective industries of biological sciences, an upcoming industry is of EPO (Erythropoietin) and ESA (Erythropoietin Stimulating Agents). EPO is a glycoprotein hormone which regulates erythropoiesis i.e. the production of Red Blood Cells (RBC). EPO is mainly produced within the human kidneys by the interstitial fibroblasts in a close association with and tubular epithelial cells. But the production of endogenous EPO is marred in case of people suffering with renal anemia as the kidney remains inflamed and also in the instance of anemia occurring due to chemotherapy amongst cancer patients. EPO is also used for placating conditions like neurological disorders, post cardiac surgery term and other critical illness situations.
The ESA market takes into account the EPO products and other EPO stimulating agents. The synthetic ESAs available in the market are known as rHuEPO (Recombinant Human Erythropoietin) manufactured using DNA. It is similar to the natural human EPO. In the pharmaceutical drug market, 5 variants of ESAs are most prevalent viz. epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa.
This report provides a comprehensive analysis of the ESA/EPO product market of Japan and China. The competitive environment of the industry is quite fierce and challenging. On the global level, the top notch players in the EPO market include Amgen, Roche and Johnson & Johnson with Hospira being another potential constituent.
Herein, the market dynamics viz. the key trends (strategic outlook for clinical trials, inclination towards polysialylation and focus on clinical differentiation), industry developments (development of improved biological molecules, ErepoXen Phase IIb intravenous trial underway in India and advent of biosimilars), growth drivers (increasing cases chronic kidney disease (CKD), global dialysis patient population, increasing prevalence of cancer, upcoming patent expiries of original bio drugs, rising adult population worldwide and rising healthcare expenditure) and challenges (risk of thrombosis and PRCA, requirement of extensive clinical trials for obtaining approval, abusive uses of EPO, adverse effects of EPO and escalating price pressure) are also explicated.
Amongst the respective industries of biological sciences, an upcoming industry is of EPO (Erythropoietin) and ESA (Erythropoietin Stimulating Agents). EPO is a glycoprotein hormone which regulates erythropoiesis i.e. the production of Red Blood Cells (RBC). EPO is mainly produced within the human kidneys by the interstitial fibroblasts in a close association with and tubular epithelial cells. But the production of endogenous EPO is marred in case of people suffering with renal anemia as the kidney remains inflamed and also in the instance of anemia occurring due to chemotherapy amongst cancer patients. EPO is also used for placating conditions like neurological disorders, post cardiac surgery term and other critical illness situations.
The ESA market takes into account the EPO products and other EPO stimulating agents. The synthetic ESAs available in the market are known as rHuEPO (Recombinant Human Erythropoietin) manufactured using DNA. It is similar to the natural human EPO. In the pharmaceutical drug market, 5 variants of ESAs are most prevalent viz. epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa.
This report provides a comprehensive analysis of the ESA/EPO product market of Japan and China. The competitive environment of the industry is quite fierce and challenging. On the global level, the top notch players in the EPO market include Amgen, Roche and Johnson & Johnson with Hospira being another potential constituent.
Herein, the market dynamics viz. the key trends (strategic outlook for clinical trials, inclination towards polysialylation and focus on clinical differentiation), industry developments (development of improved biological molecules, ErepoXen Phase IIb intravenous trial underway in India and advent of biosimilars), growth drivers (increasing cases chronic kidney disease (CKD), global dialysis patient population, increasing prevalence of cancer, upcoming patent expiries of original bio drugs, rising adult population worldwide and rising healthcare expenditure) and challenges (risk of thrombosis and PRCA, requirement of extensive clinical trials for obtaining approval, abusive uses of EPO, adverse effects of EPO and escalating price pressure) are also explicated.
1. ERYTHROPOIETIN (EPO)
1.1 Overview
1.2 Recombinant Human Erythropoietin (rHuEPO)
1.3 Use of EPO in Treating Anemia and other Medical Conditions
2. ESA/EPO PRODUCT MARKET SIZE
2.1 Japanese Erythropoietin Market
2.1.1 EPO Products in Market/Under Development in Japan
2.1.2 Japan’s ESA/EPO Products Market
Market Value
Market Size by Products
Market Share by Companies/Products
2.1.3 Japan’s ESA/EPO Product Market Outlook
Overall Market Forecast
Product Revenue Forecast
2.2 Chinese Erythropoietin Market
2.2.1 China’s EPO and EPIAO Market Size
EPO Market Growth
EPO Market Size by Segments
EPIAO Market Size by Segments
2.2.2 China’s EPIAO Market Outlook
Segment Outlook
-ESRD
-Pre-Dialysis
-Oncology
3. MARKET DYNAMICS
3.1 Key Trends
3.1.1 Strategic Outlook for Clinical Trials
3.1.2 Inclination towards Polysialylation
3.1.3 Focus on Clinical Differentiation
3.2 Industry Developments
3.2.1 Development of improved Biological Molecules
3.2.2 ErepoXen Phase IIb Intravenous Trial Underway in India
3.2.3 Advent of Biosimilars
3.3 Growth Drivers
3.3.1 Increasing Cases Chronic Kidney Disease (CKD)
3.3.2 Global Dialysis Patient Population
3.3.3 Increasing Prevalence of Cancer
3.3.4 Upcoming Patent Expiries of Original Bio Drugs
3.3.5 Rising Adult Population Worldwide
3.3.6 Rising Healthcare Expenditure
3.4 Challenges
3.4.1 Risk of Thrombosis and PRCA
3.4.2 Requirement of Extensive Clinical Trials for Obtaining Approval
3.4.3 Abusive Uses of EPO
3.4.4 Adverse Effects of EPO
3.4.5 Escalating Price Pressure
4. ERYTHROPOIETIN MARKET - COMPETITIVE LANDSCAPE
Competitive Overview
Market Share
5. COMPANY PROFILES
5.1 Amgen Inc.
Business Overview
Financial Overview
Business Strategies
Growth through Strategic Alliances
Capitalizing on Acquisitions
5.2 Johnson & Johnson
Business Overview
Financial Overview
Business Strategies
Financial Risk Minimization
Concentration on Long Term Growth
5.3 Roche
Business Overview
Financial Overview
Business Strategies
Focus on Innovation
Excellence in Molecular Biology
5.4 Hospira Inc.
Business Overview
Financial Overview
Business Strategies
New Product Development Strategy
Novel Drug Delivery Formants
1.1 Overview
1.2 Recombinant Human Erythropoietin (rHuEPO)
1.3 Use of EPO in Treating Anemia and other Medical Conditions
2. ESA/EPO PRODUCT MARKET SIZE
2.1 Japanese Erythropoietin Market
2.1.1 EPO Products in Market/Under Development in Japan
2.1.2 Japan’s ESA/EPO Products Market
Market Value
Market Size by Products
Market Share by Companies/Products
2.1.3 Japan’s ESA/EPO Product Market Outlook
Overall Market Forecast
Product Revenue Forecast
2.2 Chinese Erythropoietin Market
2.2.1 China’s EPO and EPIAO Market Size
EPO Market Growth
EPO Market Size by Segments
EPIAO Market Size by Segments
2.2.2 China’s EPIAO Market Outlook
Segment Outlook
-ESRD
-Pre-Dialysis
-Oncology
3. MARKET DYNAMICS
3.1 Key Trends
3.1.1 Strategic Outlook for Clinical Trials
3.1.2 Inclination towards Polysialylation
3.1.3 Focus on Clinical Differentiation
3.2 Industry Developments
3.2.1 Development of improved Biological Molecules
3.2.2 ErepoXen Phase IIb Intravenous Trial Underway in India
3.2.3 Advent of Biosimilars
3.3 Growth Drivers
3.3.1 Increasing Cases Chronic Kidney Disease (CKD)
3.3.2 Global Dialysis Patient Population
3.3.3 Increasing Prevalence of Cancer
3.3.4 Upcoming Patent Expiries of Original Bio Drugs
3.3.5 Rising Adult Population Worldwide
3.3.6 Rising Healthcare Expenditure
3.4 Challenges
3.4.1 Risk of Thrombosis and PRCA
3.4.2 Requirement of Extensive Clinical Trials for Obtaining Approval
3.4.3 Abusive Uses of EPO
3.4.4 Adverse Effects of EPO
3.4.5 Escalating Price Pressure
4. ERYTHROPOIETIN MARKET - COMPETITIVE LANDSCAPE
Competitive Overview
Market Share
5. COMPANY PROFILES
5.1 Amgen Inc.
Business Overview
Financial Overview
Business Strategies
Growth through Strategic Alliances
Capitalizing on Acquisitions
5.2 Johnson & Johnson
Business Overview
Financial Overview
Business Strategies
Financial Risk Minimization
Concentration on Long Term Growth
5.3 Roche
Business Overview
Financial Overview
Business Strategies
Focus on Innovation
Excellence in Molecular Biology
5.4 Hospira Inc.
Business Overview
Financial Overview
Business Strategies
New Product Development Strategy
Novel Drug Delivery Formants
LIST OF CHARTS
Stages of Erythropoiesis
Erythropoietin Response to Hypoxia
Japan’s ESA Market Size (2004-2010)
Japan’s ESA Market Size by Product (2010-2011)
Japan’s ESA Market Share by Product (2010-2015E)
Japan’s ESA Market Share by Company (2010-2015E)
Japan’s ESA Market Size (2012E-2015E)
Japan’s ESA Market Size by Product (2012E-2015E)
China’s EPO Market Growth (2005 and 2010)
China’s EPO Market Size by Usage Area (2007-2011)
China’s EPIAO Market Size by Usage Area (2007-2011)
Worldwide Patients with End Stage Renal Disease (2005-2010)
Causes of ESRD in the US (2011)
Dialysis Patient Population Worldwide (2005-2015E)
Number of Cancer Cases Worldwide (2007-2011)
Rising Global Adult Population Above 20 years (2007-2012E)
Global Healthcare Spending (2005-2015E)
EPO Market Share (including biobetter) by Company (2010)
Amgen’s Revenue Share by Business segment (2011)
Amgen’s Revenues and Net Income (2011)
Johnson & Johnson’s Revenue Share by Business Segments (2011)
Johnson & Johnson’s Revenues and Net Earnings (2008-2011)
Roche’s Revenue Share by Business Segments (2011)
Roche’s Revenues and Net Income (2007-2011)
Hospira’s Revenue Share by Business Segments (2011)
Hospira’s Revenues & Net Income (2007-2011)
Stages of Erythropoiesis
Erythropoietin Response to Hypoxia
Japan’s ESA Market Size (2004-2010)
Japan’s ESA Market Size by Product (2010-2011)
Japan’s ESA Market Share by Product (2010-2015E)
Japan’s ESA Market Share by Company (2010-2015E)
Japan’s ESA Market Size (2012E-2015E)
Japan’s ESA Market Size by Product (2012E-2015E)
China’s EPO Market Growth (2005 and 2010)
China’s EPO Market Size by Usage Area (2007-2011)
China’s EPIAO Market Size by Usage Area (2007-2011)
Worldwide Patients with End Stage Renal Disease (2005-2010)
Causes of ESRD in the US (2011)
Dialysis Patient Population Worldwide (2005-2015E)
Number of Cancer Cases Worldwide (2007-2011)
Rising Global Adult Population Above 20 years (2007-2012E)
Global Healthcare Spending (2005-2015E)
EPO Market Share (including biobetter) by Company (2010)
Amgen’s Revenue Share by Business segment (2011)
Amgen’s Revenues and Net Income (2011)
Johnson & Johnson’s Revenue Share by Business Segments (2011)
Johnson & Johnson’s Revenues and Net Earnings (2008-2011)
Roche’s Revenue Share by Business Segments (2011)
Roche’s Revenues and Net Income (2007-2011)
Hospira’s Revenue Share by Business Segments (2011)
Hospira’s Revenues & Net Income (2007-2011)
LIST OF TABLES
Drugs for anemia associated with chronic renal failure in Japan
Mircera Assumptions (2010-2015E)
Nesp Assumption (2010-2015E)
Espo Assumption (2010-2015E)
Epogin Assumption (2010-2015E)
Epoetin-alpha BS Assumptions (2010-2015E)
Japanese ESA Market Share by Product and by Company (2010-2015E)
Japan’s ESA Product Revenues (2012E-2015E)
China’s EPIAO Market Model for ESRD (2007-2011)
China’s EPIAO Market Model for Pre-Dialysis (2007-2011)
China’s EPO Market Model for Oncology (2007-2011)
China’s EPIAO Opportunity Model for ESRD (2012E-2014E)
China’s EPIAO Opportunity Model for Pre-Dialysis (2012E-2014E)
China’s EPO Opportunity Model for Oncology (2012E-2014E)
Development of Novel Forms of Erythropoietin
Recombinant and Improved Formulations of Erythropoietin
Biosimilar Epoetins Currently Approved by the European Medicines Agency
Biosimilar Share (by Value) of the Short-acting Erythropoiesis-stimulating Agent Market in the EU G5 Countries (2011)
Risk Factors for CKD
Expiry of Bio Drugs Patents in the Global Market (2013-2015)
Drugs for anemia associated with chronic renal failure in Japan
Mircera Assumptions (2010-2015E)
Nesp Assumption (2010-2015E)
Espo Assumption (2010-2015E)
Epogin Assumption (2010-2015E)
Epoetin-alpha BS Assumptions (2010-2015E)
Japanese ESA Market Share by Product and by Company (2010-2015E)
Japan’s ESA Product Revenues (2012E-2015E)
China’s EPIAO Market Model for ESRD (2007-2011)
China’s EPIAO Market Model for Pre-Dialysis (2007-2011)
China’s EPO Market Model for Oncology (2007-2011)
China’s EPIAO Opportunity Model for ESRD (2012E-2014E)
China’s EPIAO Opportunity Model for Pre-Dialysis (2012E-2014E)
China’s EPO Opportunity Model for Oncology (2012E-2014E)
Development of Novel Forms of Erythropoietin
Recombinant and Improved Formulations of Erythropoietin
Biosimilar Epoetins Currently Approved by the European Medicines Agency
Biosimilar Share (by Value) of the Short-acting Erythropoiesis-stimulating Agent Market in the EU G5 Countries (2011)
Risk Factors for CKD
Expiry of Bio Drugs Patents in the Global Market (2013-2015)
